Clinical Trial Update: Megakaryocytic Progenitor Cells for Prophylaxis and Treatment of Thrombocytopenia [Phase 2, Phase 3]

View source ↗

Summary

A Phase 2/Phase 3 clinical trial update evaluating megakaryocytic progenitor cells for prophylaxis and treatment of thrombocytopenia, sponsored by Nanfang Hospi…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Thrombocytopenia

Drugs mentioned

• Megakaryocytic Progenitor Cells

Snippet

Sponsor: Nanfang Hospital, Southern Medical University | Conditions: Hematological Diseases, Thrombocytopenia | Phase 2, Phase 3 | Status: UNKNOWN